{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.42","value":"1.45"},{"groupId":"OG001","spread":"109.19","value":"1.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"CYCLE 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"75.30","value":"2.41"},{"groupId":"OG001","value":"1.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"CYCLE 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.17"},{"groupId":"OG001","value":"2.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"CYCLE 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"CYCLE 8"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"CYCLE 11"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose via intravenous (IV) infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG000","title":"Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)"},{"description":"Participants with RRMM received belantamab mafodotin as dose of 3.4 mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG001","title":"Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Cycle 2, Cycle 5, Cycle 8 and Cycle 11","title":"Part 1: Trough Plasma Concentration (Ctrough) Following Repeat Dose Administration of Belantamab Mafodotin (ADC)","type":"SECONDARY","unitOfMeasure":"ug/mL"}